If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
3.475    0.145 (4.35%)
Bid:
3.315
Ask:
3.705
Spread: 0.39 (11.765%)
Market Cap: £21.68m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Total Voting Rights

16 Aug 2022 08:03

RNS Number : 0957W
Immupharma PLC
16 August 2022
 

RNS | 16 August 2022 

ImmuPharma plc

Total Voting Rights

ImmuPharma plc ("ImmuPharma" or "the Company"), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM.

Consequently, the Company's issued share capital now comprises, 327,403,115 Ordinary Shares with one voting right each and 284,984,933 deferred shares with no rights to vote. As the Company does not hold any shares in treasury, the total number of voting rights in the Company is also 327,403,115 and this figure of Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Ends

For further information, please contact:

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer & Chairman

+ 44 (0) 207 152 4080

Lisa Baderoon, Head of Investor Relations & Non-Executive Director

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 3550

 

 

+44 20 3650 3650

 

 

+44 (0) 1483 413500

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRSFIESIEESEEA
Date   Source Headline
19th Aug 20214:35 pmRNSPrice Monitoring Extension
17th Aug 20218:50 amRNSNotification of Major Holdings
12th Aug 20217:00 amRNSFDA approves the Lupzuor™ PK study
10th Aug 20214:40 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSBoard Changes
16th Jul 20217:00 amRNSBoard Appointment
28th Jun 202112:27 pmRNS2021 RESULT OF ANNUAL GENERAL MEETING -REPLACEMENT
28th Jun 202111:03 amRNS2021 RESULT OF ANNUAL GENERAL MEETING
24th Jun 20214:41 pmRNSSecond Price Monitoring Extn
24th Jun 20214:36 pmRNSPrice Monitoring Extension
24th Jun 20217:00 amRNSUpdate: Lupzuor™ PK study
2nd Jun 20217:00 amRNSNotice of AGM and posting of Report & Accounts
24th May 20217:00 amRNSDirector Retirement
29th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
25th Feb 20214:41 pmRNSSecond Price Monitoring Extn
25th Feb 20214:35 pmRNSPrice Monitoring Extension
9th Feb 20217:00 amRNSUpdate- scheduled Phase 3 trials in lupus patients
18th Jan 20217:00 amRNSAppointment of Company Secretary
4th Jan 20217:00 amRNSHolding(s) in Company
2nd Dec 20207:00 amRNSIMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
30th Nov 20207:00 amRNSTotal Share Capital Notification
26th Nov 20207:00 amRNSGrant of Share Options & PDMR dealing
24th Nov 20207:00 amRNSConversion of Convertible Security
23rd Nov 20207:00 amRNSConversion of Convertible Security
20th Nov 20207:00 amRNSUpdate : FDA confirms 4 Dec for Type ‘A’ meeting
18th Nov 20207:00 amRNSTotal Share Capital Notification - Replacement
10th Nov 20207:00 amRNSUpdate on submission to the FDA
30th Sep 20207:01 amRNSTotal Share Capital Notification
30th Sep 20207:00 amRNSInterim Results
29th Sep 20207:00 amRNSShare Subscription into Incanthera plc
22nd Sep 20207:00 amRNSRepayment of Convertible Security
11th Sep 20207:59 amRNSUpdate on submission to the FDA
10th Sep 202010:59 amRNSConversion of Convertible Security
9th Sep 20201:45 pmRNSConversion of Convertible Security
8th Sep 20203:49 pmRNSHolding(s) in Company
8th Sep 20209:00 amRNSDirector/PDMR Shareholding / TR -1
7th Sep 20207:02 amRNSPlacing - update; related party transaction)
3rd Sep 20207:00 amRNSConversion of Convertible Security
2nd Sep 20207:00 amRNSPlacing to raise £6.5 million
1st Sep 20207:00 amRNSHolding(s) in Company
27th Jul 20207:00 amRNSFDA submission for Special Protocol Assessment
18th Jun 202011:31 amRNS2020 AGM – ALL RESOLUTIONS PASSED
16th Jun 20207:00 amRNSTotal Share Capital Notification
11th Jun 202012:00 pmRNSTR-1 Notification of major holdings
11th Jun 20207:00 amRNSSTRAT. INVTS FROM 2 SPECIALIST US H'CARE INVESTORS
5th Jun 20207:00 amRNSChange of Registered Office Address

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.